Close Menu

NEW YORK – Illumina said yesterday that it has partnered with Chinese molecular diagnostics firm AnchorDx to develop clinical oncology tests for the Chinese market.

Under the terms of the strategic collaboration, AnchorDx, based in Guangzhou in southern China, will use Illumina's MiSeqDx sequencing system to develop in vitro diagnostic cancer test kits and data analysis software. AnchorDx plans to develop genomic cancer tests that range from screening to diagnostic testing to treatment monitoring.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Jul
30
Sponsored by
Mission Bio

This webinar will outline a project that performs large-scale and integrative single-cell genome and transcriptome profiling of pediatric acute lymphoblastic leukemia (ALL) cases at diagnosis, during drug treatment, and in case of relapse.

Jul
31
Sponsored by
Thermo Fisher Scientific

This webinar will provide a first-hand look at how a molecular laboratory validated and implemented a targeted next-generation sequencing-based myeloid assay to expedite the assessment of myeloid malignancies and assist in the understanding of myeloid cancers.